Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
Checked against the public recordLast updated Apr 4, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Mirati Therapeutics Inc.
- Interventions being studied
- Drug: MRTX849; Drug: TNO155
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer) * Unresectable or metastatic disease * No available treatment with curative intent * Adequate organ function Exclusion Criteria: * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * Other active cancer * Cardiac abnormalities
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 002-805Los Angeles, California
- Local Institution - 002-803Orange, California
- Local Institution - 002-828Chicago, Illinois
- Local Institution - 002-942Wichita, Kansas
- Local Institution - 002-804Boston, Massachusetts
- Local Institution - 002-808Boston, Massachusetts
- Local Institution - 002-811Novi, Michigan
- Local Institution - 002-809 DCity of Saint Peters, Missouri
- Local Institution - 002-809 BCreve Coeur, Missouri
- Local Institution - 002-809 ASt Louis, Missouri
- Local Institution - 002-809 CSt Louis, Missouri
- Local Institution - 002-809St Louis, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 4, 2025. Always confirm current availability with the study team.